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Abstract
 
To study whether changes in the structure of a T cell receptor (TCR) at a single peptide-con-
tacting residue could affect T cell priming with antigenic peptide, we made transgenic mice
with a point mutation in the TCR 
 
a
 
 chain of the D10.G4.1 (D10) TCR and bred them to
D10 
 
b
 
 chain transgenic mice. The mutation consisted of a leucine to serine substitution at po-
sition 51 (L51S), which we had already established contacted the second amino acid of the pep-
tide such that the response to the reference peptide was reduced by 
 
z
 
100-fold. A mutation in
the reference peptide CA134–146 (CA-WT) from the arginine at peptide position 2 to glycine
(R2G) restored full response to this altered TCR. When we examined in vitro priming of na-
ive CD4 T cells, we observed that the response to doses of CA-WT that induced T helper cell
type 1 (Th1) responses in naive CD4 T cells from mice transgenic for the D10 TCR gave only
Th2 responses in naive CD4 T cells derived from the L51S. However, when we primed the
same T cells with the R2G peptide, we observed Th1 priming in both D10 and L51S naive
CD4 T cells. We conclude from these data that a mutation in the TCR at a key position that
contacts major histocompatibility complex–bound peptide is associated with a shift in T cell
differentiation from Th1 to Th2.
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Introduction
 
The TCR of CD4 T lymphocytes recognizes immuno-
genic peptide sequences bound within the groove of MHC
class II molecules (1). Such recognition results in a signal
that is transmitted through the TCR, activates intracellular
signal transduction pathways, and culminates in the prolif-
eration and differentiation of CD4 T cells into effector cells
that execute many functions (2). Naive CD4 T cells may
differentiate into either Th1 or Th2 cells (3). Th1 cells me-
diate inflammatory responses, activate macrophages, and
stimulate cell-mediated immunity. Th2 cells activate B
cells, stimulate humoral immunity, and are prominent me-
diators of allergic responses (4). The choice of differentia-
tion into either Th1 or Th2 cells is a crucial step that deter-
mines the direction of the subsequent adaptive immune
response. This choice is influenced by many factors includ-
ing the interaction between the TCR and the peptide–
MHC complex (5). The cytokine environment where the
CD4 T cell meets its ligand is as important as the details of
the direct engagement of its TCR by that ligand. In vitro
studies have shown that the predominance of IL-4 or IL-6
drives Th2 differentiation, whereas the predominance of
IFN-
 
g
 
 or IL-12 drives Th1 differentiation. The source of
the initial IL-4 in vivo can be either NK1.1
 
1
 
 CD4 T cells
(6), or naive CD4 T cells that have encountered IL-6–pro-
ducing APCs (7). The source of the initial IFN-
 
g
 
 can be
NK cells, CD8 T cells, or naive CD4 T cells that have en-
countered IL-12–producing APCs (8). Different pathogens
trigger different innate immune mechanisms that favor one
cytokine environment over the other. These mechanisms
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are probably related to the antigenic makeup of the patho-
gen, its route of entry, and the type and condition of the
APC that initially responds to its presence (9, 10).
We are beginning to understand the factors central to the
TCR–peptide–MHC complex that influence CD4 T cell
differentiation. In general, a longer duration of contact be-
tween the TCR and its ligand results in a full signal
through the TCR and subsequent Th1 differentiation (5,
11). Partial signals favor Th2 differentiation. The duration
of contact is in turn influenced by several factors such as: (a)
high density of peptide–MHC ligand on the surface of the
APC, (b) the stability of the complex between the peptide
and the MHC molecule, and (c) a longer half-life of TCR–
peptide–MHC complexes.
Only three to five amino acids within a peptide bound in
the groove of MHC molecules face outwards into the sol-
vent for potentially direct contacts with TCR amino acids
(12–14). Similarly, although many amino acids constitute
the framework of the TCR 
 
a
 
 and 
 
b
 
 chains, only a few
amino acids have been established to directly contact pep-
tide amino acids (15–21). Functional studies that supported
these findings came from experiments with altered peptide
ligands (APLs).
 
1 
 
APLs are peptide variants that have been
structurally designed to contain single amino acid substitu-
tions at key TCR contact residues (22). APLs are still pre-
sented by the same MHC class II molecule and recognized
by the same TCR. However, this recognition results in
marked alterations in the nature of the signal received by
the TCR. APLs were first shown to stimulate IL-4 produc-
tion from Th2 clones that were capable of providing B cell
help but failed to induce proliferation (23). APLs also stim-
ulated Th1 clones to express IL-2 receptor and exhibit cy-
totoxic function without stimulating proliferation or cy-
tokine production (24). The biochemical basis for the
selective induction of these effector functions was shown to
lie in incomplete phosphorylation of the CD3 chains, lack
of recruitment and phosphorylation of Src homology 2
(SH2)-containing kinases, and distinct quantitative differ-
ences in calcium mobilization patterns (22). Whereas low
doses of agonist peptides resulted in phosphorylation of ty-
rosine residues in the TCR-associated 
 
z
 
 chain and the ty-
rosine kinase ZAP-70, 100–1,000-fold higher doses of par-
tial agonist peptides were required to observe the same
effect.
It was further shown that stimulation of CD4 T cells by
APLs versus agonist peptides influenced CD4 T cell differ-
entiation. These observations supported previous studies
where the MHC haplotype of the APC was found to influ-
ence CD4 T cell differentiation (25). I-A
 
s
 
 molecules that
bound human collagen IV–derived immunogenic peptides
20,000 times more avidly than I-A
 
b 
 
favored differentiation
of responding CD4 T cells along the Th1 path. Increasing
the dose of antigen by immunizing I-A
 
b
 
 mice with higher
 
doses of peptide was capable of generating Th1 responses.
At a given dose, agonist peptides that formed high affinity
interactions with the MHC molecule could engage the
TCR longer, favoring Th1 differentiation, whereas APLs
having altered affinities either to the presenting MHC mol-
ecule or to the TCR favored Th2 differentiation (26). Sim-
ilarly, by varying the dose of a given peptide (agonist or
APL), higher doses were shown to favor Th1 differentia-
tion, whereas lower doses favored Th2 differentiation (27).
To accomplish the same effect, the dose of the partial ago-
nist peptide had to be 100–1,000-fold higher than the full
agonist peptide. The differential outcome of CD4 T cell
differentiation was also associated with biochemical alter-
ations proximal to the TCR (28). Thus, the density and
stability of interactions between the peptide and the MHC
influence signals generated through the TCR.
In summary, all of the above studies have dissected the
role of the trimolecular TCR–peptide–MHC complex on
CD4 T cell differentiation by introducing changes in the
peptide–MHC component. These changes are in turn in-
terpreted by the TCR, as evidenced in qualitative and
quantitative changes in the resultant intracellular biochemi-
cal signals. The direct change in the TCR itself described
in this study is a novel approach to address the following
question: Can two different TCRs recognize the same
MHC–peptide ligand with different outcomes? Similar to
the design of APLs, we have designed an altered TCR by
substituting one amino acid in the TCR 
 
a
 
 chain at a key
position that contacts MHC-bound peptide. We describe
the behavior of this altered TCR compared with its parent
TCR by generating transgenic mice bearing either TCR
and studying the proliferation and differentiation of puri-
fied naive CD4 T cells from these two transgenic mice
stimulated by the same peptide–MHC ligand. Whereas the
parent TCR bearing CD4 T cells became Th1-like at high
doses of peptide, the altered TCR bearing CD4 T cells be-
came Th2-like at those same doses. Thus, subtle variations
in the TCR can influence the outcome of CD4 T cell dif-
ferentiation.
 
Materials and Methods
 
Mutagenesis of the D10.G4.1 TCR 
 
a
 
 Chain.
 
The mutagenesis
of the D10.G4.1 (D10) TCR 
 
a
 
 chain has been described previ-
ously (29). In brief, mutagenesis was performed using the over-
lapping extension method. The D10 TCR 
 
a
 
 chain was used as a
template DNA. The mutation was produced by standard PCR
methods to produce a substitution at amino acid position 51 of
leucine to serine (L51S) in the TCR 
 
a
 
 chain. The mutagenesis
was verified by DNA sequencing.
 
Transgenic Mice.
 
The D10 transgenic mice were generated by
microinjection of the rearranged genes encoding the D10 
 
a
 
 and
 
b 
 
chain TCR as described (15). Similarly, the L51S 
 
a
 
 chain car-
rying the transgene was microinjected into day 1 C3H/B6 em-
bryos. The transgenic founder was backcrossed to B10.BR and
further backcrossed to single D10 
 
b
 
 chain transgenic mice (D10
 
b
 
 chain transgenic mice are described in reference 15). Both D10
and L51S TCR transgenic mice were further backcrossed to
C
 
a
 
2/2
 
 129s mice. Homozygous C
 
a
 
2/2
 
, either carrying the trans-
 
1
 
Abbreviations used in this paper:
 
 APL, altered peptide ligand; D10,
D10.G4.1; L51S, leucine to serine substitution at position 51; pMCC,
moth cytochrome c peptide; R2G, arginine to glycine substitution at po-
sition 2. 
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genes or not, were selected for further breeding. The lines were
maintained by breeding transgenic C
 
a
 
2/2
 
 mice with nontrans-
genic C
 
a
 
2/2
 
 mice. Transgenic mice were identified by screening
tail DNA by PCR for the presence of the transgene using D10
TCR 
 
a
 
 and 
 
b
 
 chain–specific primers. For the 
 
a
 
 chain, the for-
ward primer sequence was 5
 
9
 
 of the ATG, and the reverse primer
sequence was 3
 
9
 
 of J
 
a
 
 within the intron between J
 
a
 
 and C
 
a
 
.
The sequences were as follows: D10 V
 
a
 
 forward primer,
5
 
9
 
TTTCTCCCAAACTTCAGTCTA3
 
9
 
, and D10 V
 
a
 
 reverse
primer, 5
 
9
 
GCTCTGGTCATTGGCACGAT3
 
9
 
. For the 
 
b
 
 chain,
the forward primer sequence was within the leader, and the re-
verse primer sequence was 3
 
9
 
 of J
 
b
 
 within the intron between J
 
b
 
and C
 
b
 
. The sequences were as follows: D10 V
 
b
 
 forward primer,
5
 
9
 
-GCATTCTAGATGGTCCCAAGATGGGC-3
 
9
 
, and D10
V
 
b
 
 reverse primer, 5
 
9
 
-TTAAGGATCCACTCTGCTAAG-
GTTTTCTGC-3
 
9
 
. PCR conditions were 1 min at 94
 
8
 
C, 2 min
at 55
 
8
 
C, and 2 min at 72
 
8
 
C for 40 amplification cycles.
 
Peptides.
 
Peptides were synthesized and purified by the W.M.
Keck Biotechnology Resource Laboratory at the Yale School of
Medicine using tBOC chemistry. Peptides were characterized by
receptor protein (RP)-HPLC, amino acid analysis, and fast atom
bombardment (FAB) mass spectroscopy. The sequence of the ref-
erence peptide CA134–146 (CA-WT) is HRGAIEWEGIESG,
and of the mutated peptide with arginine to glycine at position 2
(R2G) is HGGAIEWEGIESG.
 
Isolation of Naive CD4 Transgenic T Cells.
 
12–14-wk-old
D10.TCR or L51S.TCR transgenic mice were killed, and their
spleens and LNs were removed. Single cell suspensions were pre-
pared and enriched for CD4 T lymphocytes by magnetic bead
depletion after staining with antibodies TIB-146 or TIB-164
(anti-B220), TIB-210 or TIB-105 (anti-CD8), 2.4-G2 (anti-Fc
receptor), and 10.2.16 (anti–I-A
 
k
 
), followed by anti–mouse IgG,
anti–rat IgG, and anti–rat IgM coated magnetic beads (BioMag;
PerSeptive Biosystems). Naive CD4 T cells were sorted by FAC-
Star
 
PLUS™
 
 (Becton Dickinson) after staining with filter-sterilized bi-
otinylated Mel-14 (anti–L-selectin), followed by PE-conjugated
streptavidin (Caltag) and FITC–conjugated anti-V
 
a
 
2 TCR (BD
PharMingen). V
 
a
 
2
 
1
 
Mel-14
 
high
 
 cells were collected and cultured.
 
Flow Cytometry FACScan™ Analysis.
 
Single cell suspensions
from the spleens and LNs of D10 or L51S TCR transgenic mice
were stained either before or after enrichment of CD4 T cells
with any of the following antibodies: biotinylated mAb 3D3 (clo-
notypic anti-TCR mAb specific to D10 and L51S TCRs) (30),
FITC-conjugated anti-V
 
a
 
2 TCR (BD PharMingen), biotiny-
lated anti-V
 
b
 
8.1,8.2 TCR (BD PharMingen), Quantum red–
conjugated anti-CD4 (Sigma-Aldrich), PE-conjugated anti-CD8
 
a
 
(GIBCO BRL and Life Technologies), or FITC-conjugated anti–
TCR 
 
b
 
 chain (H57; BD PharMingen). Biotinylated mAb stain-
ing was followed by PE-conjugated streptavidin (Caltag). Stained
cells were analyzed on a FACScan™ (Becton Dickinson), and
collected events were analyzed using CELLQuest™ software
(Becton Dickinson).
 
T Cell Proliferation Assays.
 
All T cell proliferation assays were
performed in 96-well U-bottomed plates (Becton Dickinson)
with 5 
 
3
 
 10
 
4
 
 CD4 T cells per well. Total splenocytes from syn-
geneic nontransgenic C
 
a
 
2/2
 
 littermates were used as a source of
APCs after irradiation at 2,000 rads. 10
 
5
 
 irradiated splenocytes
were added per well followed by the addition of varying doses of
CA-WT or R2G peptide ranging from 100 to 10
 
2
 
3
 
 
 
m
 
M, in a fi-
nal volume of 200 
 
m
 
l per well. The cultures were left undisturbed
for 72 h, at which time each well was pulsed with 0.5 
 
m
 
Ci of
[
 
3
 
H]thymidine (NEN Life Science Products). The wells were
harvested 18 h later onto printed filter mats (Wallac) using a 96-
well cell harvester (TomTec). The filter mats were sealed in sam-
ple bags (Wallac), and the incorporated radioactivity was counted
using a 1205 Betaplate liquid scintillation counter (Wallac).
 
Mini Double Cultures.
 
The minicultures were adapted from a
protocol designed by Dr. Kim Bottomly’s research group (25) as
a method to provide naive CD4 T cells with both a primary and
a secondary stimulation in vitro, and assess their subsequent dif-
ferentiation into either Th1 or Th2 cells. All mini double cultures
were performed in duplicate in 96-well U-bottomed plates (Bec-
ton Dickinson) and in a total volume of 200 
 
m
 
l/well. 5 
 
3
 
 10
 
4
 
FACS
 
®
 
-sorted naive D10 TCR or L51S TCR transgenic CD4 T
cells were cultured with 10
 
5
 
 irradiated syngeneic nontransgenic
C
 
a
 
2/2
 
 littermate splenocytes and 25 U/ml IL-2 in Click’s modi-
fied EHAA medium supplemented with 5% FCS (Gemini Bio-
products, Inc.). CA-WT or R2G peptide was added to each well
at varying doses ranging from 100 to 10
 
2
 
3
 
 
 
m
 
M. Cells were rested
on day 4 by removing the entire 200 
 
m
 
l of culture supernatants
for cytokine analysis, and adding fresh 10
 
5
 
 irradiated syngeneic
C
 
a
 
2/2
 
 splenocytes without IL-2 for 2 d. The cultures were then
restimulated on day 6 by removing 100 
 
m
 
l of the culture superna-
tant and replacing it with 100 
 
m
 
l medium containing 10
 
5
 
 irradi-
ated syngeneic C
 
a
 
2/2
 
 splenocytes to a final concentration of 25
U/ml IL-2 and 100 
 
m
 
M of R2G peptide. Culture supernatants
excluding the cells were again removed for cytokine analysis on
day 4 after the secondary stimulation, and cultures were thus ter-
minated on day 10.
 
ELISA.
 
The levels of IL-4 or IFN-
 
g
 
 in the culture superna-
tants after primary or secondary stimulation were measured by
ELISA. 96-well Nunc-Immuno plates (Nalge Nunc Interna-
tional) were coated with 100 
 
m
 
l/well of capturing anti–IL-4 mAb
(11B11) and anti–IFN-
 
g
 
 mAb (HB-170) at 6 
 
m
 
g/ml in PBS at
4
 
8
 
C for 18 h. The plates were washed with 0.1% solution of
Tween 20 (Sigma-Aldrich) in PBS, and blocked with 1% BSA
(Sigma-Aldrich) in PBS for 1 h at 37
 
8
 
C. 50 ml of culture superna-
tants and IL-4 or IFN-g standards was then added and incubated
at 48C for 18 h. Twofold dilutions of murine IL-4 or IFN-g (BD
PharMingen) of known concentrations were used as standards.
Cytokine–antibody complexes were detected by the addition of
biotinylated anti–murine IL-4 or IFN-g (BD PharMingen), fol-
lowed by peroxidase-conjugated streptavidin (Zymed Laborato-
ries), and visualization after the addition of o-phenylenediamine
dihydrochloride from tablets (Sigma-Aldrich). Color develop-
ment was stopped with 3 M H2SO4. Absorbance at 492 nm was
measured on an ELISA reader (ELx800; Biotek Instruments,
Inc.). The supernatant concentrations of IL-4 or IFN-g were cal-
culated by extrapolating absorbance values from the standard
curve plotting concentration versus absorbance.
Intracellular Cytokine Staining. Double cultures were set up
with naive sorted CD4 T cells and irradiated syngeneic Ca2/2
splenocytes in the presence of 25 U/ml IL-2, in 24-well flat-bot-
tomed plates (Becton Dickinson), and in a total volume of 2 ml
EHAA medium/5% FCS (Gemini Bioproducts, Inc.). The cul-
tures were primed with 10 mM CA-WT peptide and restimu-
lated with 0.05 mg/ml PMA (Sigma-Aldrich) and 0.5 mg/ml
Ionomycin (Calbiochem). 10 mg/ml brefeldin A (Epicenter
Technologies) was added 4 h later, and the cells were stained after
an additional 4 h using the FIX & PERM Cell Permeabilization
kit (Caltag) and the following antibodies: Quantum red–conju-
gated anti-CD4 (Sigma-Aldrich), FITC-conjugated anti–IFN-g
(IgG1; BD PharMingen), PE-conjugated anti–IL-4 (IgG2b; BD
PharMingen), and the isotype control immunoglobulin antibod-
ies PE-conjugated rat IgG2b, and FITC-conjugated rat IgG1.
Stained cells were immediately analyzed on a FACScan™ (Bec-2068 CD4 T Cells Bearing an Altered TCR Differentiate into Th2 Effectors
ton Dickinson). CD41 T cells were gated and analyzed using
CELLQuest™ software (Becton Dickinson).
Results
The Basis for Selecting the Amino Acid Substitution for the
Generation of the Altered TCR. D10 is a cloned T cell line
that recognizes the core nine–amino acid peptide sequence
derived from a peptide within the chicken conalbumin pro-
tein (CA134–146) and presented by the MHC class II mol-
ecule I-Ak (29–31). The clone also exhibits alloreactivity
towards other MHC class II molecules such as I-Ab, v, p, q, d.
We have previously described the full characterization of
the interaction of the D10 TCR with its peptide–MHC
ligand by extensive mutagenesis of the TCR (15, 29), its
MHC ligands (16), and the peptide itself (29, 32). The
nine–amino acid core of the peptide derived from conalbu-
min has previously been referred to as CA-WT and has the
sequence HRGAIEWEG. We have previously identified
positions p1, p4, p6, and p9 of the CA-WT peptide as
MHC binding residues, and p2, p5, and p8 of the peptide
as TCR contact residues (15) (Fig. 1). The contact of pep-
tide position 2 with the a chain CDR2 was later confirmed
by site-directed mutagenesis of amino acid 51 of the TCR
a chain (29).
Another T cell clone, AK8, described previously by our
laboratory, is related to D10, and both clones have the
same TCR b chain but differ in their a chain by 7 amino
acids within the first NH2-terminal 70 residues, including 1
that was in the a chain CDR2 at position 51 (16). A sepa-
rate mutation was thus introduced at this position from the
leucine present in D10 to the serine present in AK8. This
mutated a chain was transfected along with the parent b
chain into 4G4 T cell hybrids to generate the T cell hybrid
L51S (29). We showed that amino acid 51 in the CDR2 of
the TCR a chain interacted with the peptide at p2 (29).
The proliferative response of L51S T cells was 150-fold
lower to CA-WT than that of the parent D10 T cells. One
particular peptide variant, R2G, was of interest since it re-
stored the proliferative response of L51S T cells to levels
and at doses similar to those obtained with D10 cells.
Based on the information and results summarized above,
we have generated L51S TCR transgenic mice in this study
that bear the single mutation at position 51 of the TCR a
chain and are restricted to I-Ak. These mice were bred onto
a Ca2/2 background to ensure that no other endogenous a
chains were used for pairing with the parent b chain. In ad-
dition, D10 TCR transgenic mice that have been described
previously (15) were also bred onto a Ca2/2 background
for comparison. These mice serve as a good model for
studying two TCRs that have the same ligand specificity
and exploring different aspects of their thymic development
as well as their behavior in secondary lymphoid tissues. In
this study, we explore the influence of this single amino
acid substitution at a peptide contact site on naive CD4 T
cell differentiation.
An Amino Acid Substitution from L to S at Position 51 of the
TCR a Chain Results in the Reduction of TCR Transgenic
CD4 T Lymphocyte Numbers in Secondary Lymphoid Tissues.
The percentage of transgenic T cells in the spleens and LNs
was detected by staining with the clonotypic D10 TCR-
specific mAb 3D3. Of the total LN cells, 15% were 3D31
in L51S mice compared with 25% 3D31 in D10 mice.
Two-color FACS® analysis on CD4 T cell–enriched prep-
arations from the LNs of L51S and D10 mice showed that
after enrichment, 90% of the preparation was transgenic
CD413D31 in D10 (Fig. 2 A), and 25% was transgenic
CD413D31 in L51S mice (Fig. 2 B). The mean fluores-
cence intensities of 3D3 were similar: 56.36 for L51S, and
66.70 for D10. Furthermore, within the CD4 population
of L51S LN cells, there were two subpopulations:
CD413D31 and CD413D32. Therefore, in addition to
the already reduced numbers of CD4 T cells in the periph-
eral lymphoid tissues of L51S mice, there was a further di-
Figure 1. A schematic repre-
sentation of the CA-WT 9-mer
peptide amino acid sequence
showing both the D10 TCR
contact and I-Ak MHC class II
contact residues. The figure is
adapted from reference 15. The
peptide amino acid residues that
contact I-Ak are at positions 1, 4,
6, and 9, and labeled P1, P4, P6, and P9. Those that contact the TCR are
at positions 2, 5, and 8. The L51S mutation affects the CDR2 region of the
D10 TCR a chain, which contacts position 2 in the CA-WT peptide.
Figure 2. CD4 T cells in L51S TCR transgenic mice are markedly re-
duced in numbers. CD4 enriched cells from the LNs of D10 (A and C) or
L51S (B and D) TCR transgenic mice were stained with Quantum red–
conjugated anti-CD4 and biotinylated 3D3 followed by PE-conjugated
streptavidin (A and B). LN cells were also stained simultaneously with
Quantum red–conjugated anti-CD4, FITC-conjugated anti-Va2, and bi-
otinylated anti-Vb8.1,8.2 followed by PE-conjugated streptavidin. CD41
T cells were gated and their expression of the transgenic TCR
Va21Vb81 is shown (C and D). Log fluorescence intensity is shown on
both axes.2069 Blander et al.
lution in the percentage of transgenic CD4 T cells. The
presence of a population of cells that is CD423D31 is also
of interest. We have performed three-color staining for
3D3, CD4, and CD8 to examine whether these cells were
CD81CD423D31, and we found that they were CD82
CD423D31 (data not shown). Although at present we do
not know the significance of these cells, it is likely that
these cells have downregulated CD4 expression to avoid
deletion due to autoreactivity. The population of CD4 T
cells that did not bear the transgenic TCR was 18% of the
total CD4 enriched preparation, and it constituted 35–40%
of the total CD4 population (Fig. 2 B).
We further gated on CD4 T cells in the LNs of both
L51S and D10 mice and examined their expression of the
transgenic Va2 and Vb8 TCR chains. As expected, almost
all (97%) CD4 T cells in D10 mice expressed both the
transgenic Va2 and Vb8 TCR chains (Fig. 2 C). In sharp
contrast, only 67% of the CD4 T cells in L51S mice ex-
pressed both Va2 and Vb8 TCR chains, and 28% ex-
pressed the Vb8 TCR chain but not the Va2 TCR chain
(Fig. 2 D). The mean fluorescence intensities for Va2 were
similar: 113.26 for L51S, and 108.41 for D10. Further gat-
ing and simultaneous four-color staining showed that the
CD413D32 cells were Vb81Va22 (not shown). As these
results were obtained in Ca2/2 mice, this suggests that such
cells express an abnormal TCR made up of either a bb
homo- or heterodimer, or perhaps a bg heterodimer.
The Amino Acid Substitution in the TCR a Chain at Posi-
tion 51, One of Three Peptide Contact Sites, Alters the Prolifera-
tive Response of Transgenic CD4 T Cells. The proliferation
of L51S CD4 T cells in response to CA-WT or R2G pep-
tides was measured in the presence of irradiated syngeneic
I-Ak APCs and compared with the proliferation of D10
CD4 T cells (Fig. 3). CD4 T cells from TCR transgenic
mice had the same proliferative profile as L51S TCR–
transfected cells (29). As expected, the proliferation of L51S
CD4 T cells to the R2G mutant peptide was better than
that to CA-WT peptide. In contrast, D10 CD4 T cells re-
sponded vigorously to both peptides. The substitution of R
by G at p2 of the peptide did not influence recognition by
D10 CD4 T cells, but enhanced the response of L51S CD4
T cells by 10-fold. This proliferative response to R2G was
nonetheless 10-fold lower in L51S T cells than in D10,
possibly reflecting the lower number of transgenic CD4 T
cells in L51S CD4 enriched preparations. The proliferation
of CD4 T cells from both D10 and L51S TCR transgenic
mice in response to anti-CD3 mAb 2C11 was similar, indi-
cating that the cells were equally responsive to maximal
stimulation (data not shown, and Sant’Angelo, D.B., J.M.
Blander, and C.A. Janeway, Jr., manuscript in preparation).
The proliferation to allogeneic B6 splenocytes was similar
(not shown), indicating that similar to the L51S TCR
transfected cells (29), the L51S CD4 TCR transgenic cells
retained the response to allogeneic MHC molecules (in this
case to I-Ab).
CA-WT Peptide Primes Naive L51S CD4 T Cells to Be-
come IL-4 Producers. Naive transgenic CD4 T cells were
isolated by sorting with FACS® based on their expression
of Va2 and L-selectin (Va21Mel-141) (Fig. 4, A and B,
gates R1 and R2; for D10 and L51S CD4 transgenic T
cells, respectively). These markers were chosen for the fol-
lowing reasons. First, sorting based on Va2 expression did
not activate the T cells nonspecifically and excluded the
population of L51S CD4 T cells that was Vb81Va22. Sec-
ond, we have correlated the expression of L-selectin with
naive CD4 T cell phenotype where the cells are CD44low
CD45RBhighL-selectinhigh (33). For both L51S and D10
CD4 T cells, we established that L-selectin–expressing
naive cells were also CD45RBhigh and CD44low (not
shown).
An in vitro system of priming naive CD4 T cells was es-
tablished as described previously (27). Both L51S TCR
transgenic and D10 TCR transgenic Va21Mel-141 naive
CD4 T cells were isolated and primed with 10 mM CA-
WT peptide. After the second stimulation, CD41 T cells
were gated and examined for intracellular cytokine staining
with antibodies to IL-4 and IFN-g. Priming naive L51S
CD4 T cells with 10 mM CA-WT peptide resulted in a
major population (33%) of IL-4–producing CD4 T cells
(Fig. 5 A). A discrete population (12%) produced IFN-g,
Figure 3. Proliferation of CD4 T cells from both D10 and L51S TCR
transgenic mice in response to varying doses of CA-WT or R2G peptide
in the presence of irradiated syngeneic splenocytes. The x-axis shows the
concentration of peptide (in mM). The y-axis shows the counts per minute
(CPM) of [3H]thymidine incorporated as a measure of proliferation.
Figure 4. FACS® sorting of naive CD4 T cells from D10 or L51S
TCR transgenic mice. Sterile sorting of naive transgenic CD4 T cells by
FACS® based on the expression of the transgenic a chain (Va21) and the
naive phenotype marker L-selectin (Mel-141). CD4 T cell–enriched sus-
pensions of spleen and LNs, D10 (A) and L51S (B), were stained with
FITC-conjugated anti-Va2 and biotinylated Mel-14 followed by PE-
conjugated streptavidin. Naive transgenic Mel-141Va21 cells were gated
and collected. Log fluorescence intensity is shown on both axes.2070 CD4 T Cells Bearing an Altered TCR Differentiate into Th2 Effectors
and 9% of the cells produced both IL-4 and IFN-g. In con-
trast, a main population (28%) of D10 CD4 T cells pro-
duced IFN-g when primed at the same dose of CA-WT
peptide (Fig. 5 B).
Naive CD4 T cells were also primed at different doses of
CA-WT peptide. The dose of peptide varied 10-fold
within a range of 100–0.1 mM. Culture supernatants were
collected after the first peptide stimulation and tested for
the presence of IL-4 and IFN-g. As expected, neither D10
nor L51S naive CD4 T cells produced detectable levels of
either cytokine after primary stimulation with CA-WT
peptide (not shown). To promote maximal cytokine pro-
duction and reveal the differentiated fate of these primed T
cells, we chose to restimulate the cells with 10 mM R2G
peptide, as the proliferative response to R2G was equal or
better for D10 and L51S CD4 T cells, respectively. Prim-
ing L51S CD4 T cells with different doses of CA-WT pep-
tide showed peak IL-4 production at higher doses of CA-
WT peptide (100–10 mM) (Fig. 6 A, d). In contrast, IL-4
production by D10 CD4 T cells peaked at lower doses (1
and 0.1 mM) of CA-WT peptide (Fig. 6 B, d). When D10
and L51S CD4 T cells were primed with R2G peptide at
different doses instead of CA-WT peptide, both L51S and
D10 CD4 T cells preferentially produced IL-4 only at
lower doses of peptide (Fig. 6, C and D, respectively; d).
Culture supernatants collected after the first stimulation
with R2G contained no detectable levels of either IL-4 or
IFN-g cytokine (not shown).
R2G Peptide Primes Naive L51S CD4 T Cells to Become
IFN-g Producers at High Doses and IL-4 Producers Only at
Low Doses. Priming L51S CD4 T cells with different
doses of CA-WT peptide did not result in significant IFN-g
production (Fig. 6 A, j), whereas priming with increasing
doses of R2G resulted in 9 ng/ml IFN-g at the highest
dose of 100 mM (Fig. 6 C, j). In contrast, D10 CD4
transgenic T cells primed with increasing doses of CA-WT
or R2G peptide resulted in both cases in IFN-g production
at higher doses (Fig. 6, B and D, respectively; j). Decreas-
ing doses of both R2G and CA-WT peptide favored IL-4
production by D10 CD4 T cells (Fig. 6, B and D, respec-
tively; d).
Discussion
Recognition of immunogenic peptides by the TCR on
CD4 T lymphocytes is a complex process. Engaging the
TCR leads to the intracellular mobilization of protein ki-
nases and phosphatases that initiate and modulate different
signaling pathways. Activation through the TCR is not an
“all or none” phenomenon, but rather a gradation of sig-
naling that results in the selective stimulation of TCR-medi-
ated effector functions (34). This has been clearly demon-
Figure 5. Intracellular cytokine staining of naive L51S and D10 CD4
T cells shows the predominant population of IL-4 producers in L51S
cultures. Naive CD4 T cell cultures were primed with 10 mM CA-WT
peptide and restimulated on day 6 with PMA and ionomycin, followed
by treatment with brefeldin A. Cultured L51S naive CD4 T cells (A), or
cultured D10 naive CD4 T cells (B), were stained 6 h later with Quan-
tum red–conjugated anti-CD4, fixed with 1% paraformaldehyde, perme-
abilized, and stained with FITC-conjugated anti–IFN-g, and PE-conju-
gated anti-IL-4. CD41 T cells were gated, and their intracellular staining
for IL-4 and IFN-g is shown. The log fluorescence intensity is shown on
both axes.
Figure 6. L51S TCR transgenic naive CD4 T cells dif-
ferentiate into Th2-like IL-4–producing cells when
primed in vitro with CA-WT peptide, and produce IFN-g
when stimulated with R2G. Naive CD4 T cells were cul-
tured in the presence of varying doses of CA-WT (A and
B) or R2G peptide (C and D), irradiated syngeneic spleno-
cytes, and 25 U/ml IL-2. The primary supernatants were
collected on day 4 and the cells were restimulated with 10
mM R2G peptide, after which the secondary supernatants
were collected on day 4 and ELISAs were performed in
duplicate to measure the concentrations of IL-4 and IFN-g.
(A and C) L51S CD4 T cell cytokine profiles; (B and D)
D10 CD4 T cell cytokine profiles. IL-4 and IFN-g con-
centrations are shown in ng/ml quantities. The concentra-
tions of peptide used for priming are shown on the x-axes.2071 Blander et al.
strated by studies with APLs where the interaction between
the peptide and the MHC is weakened, and by its influ-
ence on the signals generated by the TCR studied (22).
Here we have shown that we can directly weaken the in-
teraction between the TCR and the peptide–MHC and in-
fluence the type of differentiated effector CD4 T cell gen-
erated.
The mutation of the amino acid at position 51 of the
TCR a chain seemed to lower the affinity of the D10
TCR to its CA-WT/I-Ak ligand, as suggested by the lower
rate of proliferation of CD4 T cells carrying this mutated a
chain. We had previously shown that the leucine at posi-
tion 51 lies at the tip of the CDR2a region, and interacts
with position 2 in the CA-WT peptide (29). Mice trans-
genic for the altered TCR and the mutated a chain and
parent b chain were generated. These mice were used to
examine whether a change within a region of the TCR ac-
tively involved in ligand recognition has any effect on the
development, phenotype, and function of CD4 T cells
bearing the altered TCR. Although we have introduced
only a single change in the TCR, the influence on the de-
velopment and behavior of CD4 T cells was profound. In
TCR transgenic mice bearing the altered TCR, we ob-
served an almost 60% reduction in the total numbers of
CD4 T cells in the secondary lymphoid tissues. This is di-
rectly related to the selection events that these cells un-
dergo in the thymus. Only a small percentage of the thy-
mocytes in L51S TCR transgenic mice upregulate TCR
expression and become CD41CD81. During positive se-
lection, only 1% of these double positive cells proceed to
become single positive CD4 thymocytes in contrast to 13%
in D10 TCR transgenic mice (Sant’Angelo, D.B., J.M.
Blander, and C.A. Janeway, manuscript in preparation).
Thus, the peripheral T cell numbers in L51S TCR trans-
genic mice are low because of the inefficiency of positive
selection in the thymus.
We had previously described the generation of trans-
fected cells expressing either the D10 or the L51S TCR
(29). In this study, we found that the pattern of prolifera-
tive response of CD4 T cells from L51S TCR transgenic
mice was similar to that of L51S TCR–transfected cells.
CD4 T cells from L51S TCR transgenic mice retained the
reduced proliferative response to CA-WT. The cells did
respond better to the peptide R2G, but this response was
100-fold lower than that of CD4 T cells from D10 TCR
transgenic mice. In contrast, the proliferative response of
L51S TCR–transfected cells to R2G was almost as good as
that of D10 TCR–transfected cells (29). The proliferation
data presented here suggested that the altered TCR ex-
pressed by CD4 T cells from L51S TCR transgenic mice
possibly had a reduced affinity to the CA-WT by as much
as 1,000-fold.
The novel approach employed in this study lies in com-
paring the responses of two TCRs, which recognize the
same ligand: CA-WT peptide presented by I-Ak. The study
shows the critical effect that a change as subtle as a single
amino acid difference can have on the outcome of CD4 T
cell differentiation. The position of the amino acid substi-
tution at a peptide contact residue in the TCR highlights
the importance of key amino acid residues in not only con-
ferring T cell activation, but dictating the outcome of that
activation. At present, we do not know of any naturally oc-
curring in vivo correlates to our study. We may speculate
that if there were such subtle variations in the T cell reper-
toire, a single immunodominant epitope presented by an
APC could potentially be recognized by two CD4 T cell
clones with very similar TCRs but which, at a given den-
sity of peptide–MHC complexes, differ in their potential to
differentiate into either Th1 or Th2. The cytokine milieu
created by the activated APC may then allow the further
expansion and predominance of one clone over the other.
The stability and duration of the TCR interaction with
its peptide–MHC ligand has been shown to play a crucial
role not only in activating the T cell but also in affecting
the type of effector CD4 T cell it can produce (11). There-
fore, we predicted that the reduced proliferative response
of the L51S TCR to CA-WT peptide, which may be due
to a lower stability, duration, or affinity of the TCR inter-
action with its peptide–MHC ligand, would have an influ-
ence on the differentiation of these CD4 T cells. We ex-
amined this hypothesis in vitro under a set of well-defined
conditions previously used to determine the influence of
APLs on CD4 T cell differentiation. Based on the prolifer-
ative response of L51S CD4 T cells, we may consider R2G
as the agonist peptide for the L51S TCR, and CA-WT as
the partial agonist peptide. L51S CD4 T cells differentiated
into IFN-g producers when primed at higher doses of ago-
nist, and IL-4 producers when primed at lower doses of ag-
onist. This effect of peptide dose on CD4 T cell differenti-
ation was similar to results obtained with naive CD4 T cells
from TCR transgenic mice that recognize a peptide de-
rived from tobacco horn-worm moth cytochrome c
(pMCC) and presented by I-Eb (27). High doses of pMCC
favored Th1 differentiation, whereas low doses favored
Th2 differentiation. Furthermore, we showed that CD4 T
cells from L51S TCR transgenic mice became IL-4 pro-
ducers when primed with their APL CA-WT. This effect
of APL recognition was similarly seen after in vivo priming
of H-2S mice where immunization with a wild-type pep-
tide derived from human collagen IV led to IFN-g–pro-
ducing effector cells, while immunization with variant
APLs that bound I-AS less well led to IL-4–producing ef-
fector cells (26). Similarly, priming of naive CD4 T cells
from TCR transgenic mice in vitro with pMCC peptide
led to the same observations (35).
Our results in this study strengthen the notion that the
nature of the signal transmitted by the TCR impacts
downstream differentiation events. The results show that a
mutation in the signal transmitting receptor itself, given the
same exact ligand as the parent receptor, is sufficient to in-
fluence consequent cellular differentiation. We do not
know at this time if such a mutation affects the structural
conformation of the D10 TCR at its ligand binding sites.
Recent findings using the A6 TCR of a CD81 HLA-A2–
restricted T cell clone showed that the different signals
transmitted through this TCR upon encountering three2072 CD4 T Cells Bearing an Altered TCR Differentiate into Th2 Effectors
different APLs could not be correlated with the three-
dimensional structures of the TCR interacting with the three
APL–HLA-A2 complexes (36). The similarity of the struc-
tures in all cases led to the conclusion that ligand-induced
conformational changes in the TCR do not account for the
generation of different signals. It remains to be seen
whether the three-dimensional structure of the L51S
TCR/CA-WT/I-Ak is similar to the recently reported
crystal structure of the D10 TCR/CA-WT/I-Ak (37). The
crystal structure of D10 TCR/CA-WT/I-Ak, however, in-
dicates that the L at position 51 contacts the MHC, which
is in direct contrast to our previous findings (15, 16, 29,
32). Regardless, substituting an S for L at position 51 may
have several effects, including loss of van der Waals bonds
between the L of the TCR and the T at position 77 of
the I-Ak b chain, a possible conformational change in the
CDR2a loop, and resultant contacts with position 2 in the
CA-WT peptide, and finally disruption of the interacting
surfaces between the TCR and the MHC as a result of sub-
stituting an aliphatic residue with a small hydroxyl-bearing
side chain (Reinherz, E., personal communication). It re-
mains possible that a conformational change in the TCR
chains may be sufficient to either generate a different signal
or to induce changes in the subunits within the CD3 com-
plex such that a larger and more stable signaling complex is
not formed.
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